Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Karuna Therapeutics stock | 97.85

Own Karuna Therapeutics stock in just a few minutes.

Posted

Fact checked

Karuna Therapeutics, Inc is a biotechnology business based in the US. Karuna Therapeutics shares (KRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Karuna Therapeutics employs 19 staff and has a market cap (total outstanding shares value) of USD$2.1 billion.

How to buy shares in Karuna Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Karuna Therapeutics. Find the stock by name or ticker symbol: KRTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Karuna Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$97.85, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Karuna Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Karuna Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Karuna Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Karuna Therapeutics's share price has had significant positive movement.

Its last market close was USD$97.85, which is 1.05% up on its pre-crash value of USD$96.82 and 85.96% up on the lowest point reached during the March crash when the shares fell as low as USD$52.62.

If you had bought USD$1,000 worth of Karuna Therapeutics shares at the start of February 2020, those shares would have been worth USD$773.93 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,053.84.

Karuna Therapeutics share price

Use our graph to track the performance of KRTX stocks over time.

Karuna Therapeutics shares at a glance

Information last updated 2020-10-19.
Latest market close USD$97.85
52-week range USD$12.48 - USD$152
50-day moving average USD$78.3276
200-day moving average USD$85.4664
Wall St. target price USD$125.9
PE ratio 0.154
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-254.14

Buy Karuna Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Karuna Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Karuna Therapeutics price performance over time

Historical closes compared with the close of $97.85 from 2020-11-16

1 week (2020-11-20) 0.88%
1 month (2020-10-30) 20.52%
3 months (2020-08-28) 28.75%
6 months (2020-05-29) 4.25%
1 year (2019-11-29) 36.13%
2 years (2018-11-26) N/A
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

Is Karuna Therapeutics under- or over-valued?

Valuing Karuna Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Karuna Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Karuna Therapeutics's P/E ratio

Karuna Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Karuna Therapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Karuna Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -12.75%
Return on equity TTM -18.95%
Profit margin 0%
Book value $6.942
Market capitalisation USD$2.1 billion

TTM: trailing 12 months

Shorting Karuna Therapeutics shares

There are currently 1.6 million Karuna Therapeutics shares held short by investors – that's known as Karuna Therapeutics's "short interest". This figure is 14.2% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Karuna Therapeutics shares can be evaluated.

Karuna Therapeutics's "short interest ratio" (SIR)

Karuna Therapeutics's "short interest ratio" (SIR) is the quantity of Karuna Therapeutics shares currently shorted divided by the average quantity of Karuna Therapeutics shares traded daily (recently around 207595.8611482). Karuna Therapeutics's SIR currently stands at 7.49. In other words for every 100,000 Karuna Therapeutics shares traded daily on the market, roughly 7490 shares are currently held short.

However Karuna Therapeutics's short interest can also be evaluated against the total number of Karuna Therapeutics shares, or, against the total number of tradable Karuna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karuna Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Karuna Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1299% of the tradable shares (for every 100,000 tradable Karuna Therapeutics shares, roughly 130 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Karuna Therapeutics.

Find out more about how you can short Karuna Therapeutics stock.

Karuna Therapeutics share dividends

We're not expecting Karuna Therapeutics to pay a dividend over the next 12 months.

Karuna Therapeutics overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site